Pregabalin Capsule
Product Images NDC 71610-994

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-994). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 994 30)

Pregabalin 100 mg oral capsules bottle label showing product name, strength, dosage form, and package quantity (30 capsules). It includes storage instructions, manufacturer SciGen Pharmaceuticals Inc, and repackager Aphena Pharma Solutions - Tennessee, LLC. The label features NDC 71610-994-30 and a warning that the drug may be habit forming, designated C-V controlled substance status, for prescription use only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart depicting percent of patients improved plotted against percent improvement in pain from baseline. Four lines represent Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing comparative trends of pain improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The vertical axis shows percent of patients improved from 0 to 100, and the horizontal axis shows percent improvement in pain from baseline from 0 to 100. Two lines depict outcomes for Pregabalin and placebo respectively.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved by different levels of percent improvement in pain from baseline. It compares Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken twice a day, against a placebo group. The x-axis represents percent improvement in pain, and the y-axis represents percent of patients improved.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, illustrating differences in patient improvement over varying levels of pain relief.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing patient response distribution across varying levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph depicting responder rate percentages in Studies E1 and E3 for pregabalin treatment groups compared to placebo. The x-axis shows different dosages and treatment schedules, while the y-axis represents responder rates (%) ranging from 0% to 60%. Significant differences versus placebo are indicated with asterisks.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A chart showing seizure reduction as median percent change from baseline versus dose in mg/day for Pregabalin. The graph includes data points from four studies labeled E1, E2, and E3 with different dosing schedules (BID, TID). Seizure reduction increases with dose, with p-values indicating statistical significance for the comparisons shown.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 800 mg, 450 mg, 300 mg, and placebo. The graph compares treatment effects with separate lines for each dosing group and placebo, illustrating trends of patient improvement across varying pain reduction percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart comparing Pregabalin and placebo groups over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis represents days. The solid line corresponds to Pregabalin, and the dashed line corresponds to placebo, illustrating higher survival without LTR in the Pregabalin group.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF. Two lines are displayed: a solid line representing Pregabalin and a dashed line representing Placebo. The y-axis shows percent of subjects improved from 0 to 100%, and the x-axis shows percent improved from baseline from 0 to 100%. The Pregabalin line consistently shows a higher percent of subjects improved compared to Placebo across the improvement range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved over a range of improvement percentages from 0 to 100 on the x-axis. The y-axis represents the percent of subjects improved. Two lines are shown: a solid line for Pregabalin and a dotted line for Placebo, illustrating a higher percentage of subjects improved with Pregabalin across the improvement spectrum.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

This bar chart displays the responder rate percentage on the vertical axis for three groups: Placebo (22.6%, n=93), 2.5 mg/kg/day dose (29.1%, n=103), and 10 mg/kg/day dose (40.6%, n=96). The chart compares response rates for these doses relative to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula for calculating creatinine clearance (CLcr), involving age in years, weight in kilograms, and serum creatinine in mg/dL, with a factor adjustment for female patients by multiplying by 0.85.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of pregabalin showing its molecular framework including an amino group and carboxyl group attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.